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Abstract
Background: The Global Programme to Eliminate Lymphatic Filariasis, launched following World
Health Assembly Resolution 50.29 (WHA 50.29), has been facilitated in its progress by new
research findings, drug donations, the availability of diagnostic tools, disability management
strategies to help those already suffering and the development of partnerships. The strategy
recommended by the World Health Organization of annual treatment with a two-drug
combination has proved safe.
Discussion: Using different approaches in several countries the elimination of lymphatic filariasis
(LF) has been demonstrated to be feasible during earlier decades. These successes have been
largely overlooked. However, the programme progress since 2000 has been remarkable – upscaling
rapidly from 2 million treatments in 2000 to approximately 60 million in 2002. Around 34 countries
had active programmes at the end of 2002. It is anticipated that there will be further expansion –
but this will be dependent on additional resources becoming available. The programme also
provides significant opportunities for other disease control programmes to deliver public health
benefits on a large scale. Few public health programmes have upscaled so rapidly and so cost-
effectively (<$0.03/treatment in some Asian settings) – one country treating 9–10 million people in
a day (Sri Lanka). The LF programme is arguably the most effective pro-poor public health
programme currently operating which is based on country commitment and partnerships
supported by a global programme and alliance. Tables are provided to summarize programme
characteristics, the benefits of LF elimination, opportunities for integration with other programmes
and relevance to the Millennium Development Goals.
Summary: Lymphatic filariasis elimination is an "easy-to-do" inexpensive health intervention that
provides considerable "beyond filariasis" benefits, exemplifies partnership and is easily evaluated.
The success in global health action documented in this paper requires and deserves further support
to bring to fruition elimination of lymphatic filariasis as a public health problem and health benefits
to poor people. A future free of lymphatic filariasis will reduce poverty and bring better health to
poor people, prevent disability, strengthen health systems and build partnerships.
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Background
Intensive research over the last decade has shown the effi-
cacy of new drug combinations [2], created simple diag-
nostic tools [3] (See additional file 3), improved
knowledge of pathology [4,5] (See additional file 4) and
demonstrated that those with existing disability could
have symptoms of lymphoedema and elephantiasis alle-
viated by community home-based care [6].
The Global Programme for the Elimination of Lymphatic
Filariasis (GPELF) was established in early 2000. This fol-
lowed World Health Assembly Resolution 50.29 (WHA
50.29) in 1997 calling on the member states of the World
Health Organisation (WHO) to eliminate the disease as a
public health problem. This landmark resolution fol-
lowed the 1993 declaration by the International Task
Force for Disease Eradication (ITFDE) that lymphatic
filariasis (see Table 1) was one of the six eliminable dis-
eases [1].
The WHA resolution also prompted two major pharma-
ceutical donors to provide free donations of albendazole
globally (GlaxoSmithKline) and Mectizan® (ivermectin)
(Merck and Co. Inc.), for countries where lymphatic
filariasis and onchocerciasis (river blindness) are co-
endemic, for as long as needed (Table 2) [7,8]. These
pledges represent the largest long-term donation to a glo-
bal health care initiative and a commitment to provide
quality drugs to stop transmission of a disease. However,
both companies recognize that the provision of drugs
alone is not enough to sustain programme activity and
provide wider support to the programme.
The proportions of the total, global burden posed by lymphatic filariasis that occur in the areas covered by the World Health  Organization's regional offices for the Americas (AMRO), Eastern Mediterranean (EMRO), Africa (AFRO), South-east Asia  (SEARO) and the Western Pacific (WPRO) Figure 1
The proportions of the total, global burden posed by lymphatic filariasis that occur in the areas covered by the World Health 
Organization's regional offices for the Americas (AMRO), Eastern Mediterranean (EMRO), Africa (AFRO), South-east Asia 
(SEARO) and the Western Pacific (WPRO). Burden was estimated as the number of disability-adjusted life-years (DALY) lost 
and is shown split, in the pie chart for each region, according to the type of mosquito responsible for transmitting the causative 
parasite. Reprinted with permission from Annals of Tropical Medicine and  Parasitology, Vol. 96, Supplement No. 2, S3–S13 
(2002).
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Discussion
The development of a new strategy – time limited (at least
5 years) – annual co-administration of two drugs and the
creation of GPELF and the Global Alliance for the Elimi-
nation of Lymphatic Filariasis (GAELF) builds on success-
ful lymphatic filariasis elimination programmes in several
countries [7–9]. These countries in different endemic
areas and epidemiological settings have convincingly
demonstrated that transmission could be stopped perma-
nently. China, Japan, Korea, Thailand and the Solomon
Islands using different strategies have eliminated trans-
mission; Sri Lanka has eliminated Brugian filariasis and
smaller foci in Brazil, Malaysia, Costa Rica, Suriname and
Trinidad and  Tobago have been eliminated [10].
The establishment of a diverse partnership in 2000 to
form GAELF and the endorsement of the WHO strategic
plan created a momentum that has resulted in 34 coun-
tries establishing active programmes. The programme has
expanded rapidly with the number of people treated
annually rising from 2.9 million in 12 countries in 2000
to 28.89 million in 2001 and an estimated 60 million in
34 countries in 2002 [11]. This upscaling occurred as the
safety and tolerability of the drug combinations was con-
firmed on an increasingly large scale, as the extent of the
disease and its consequent disabling effects on poor peo-
ple were recognised, and as the magnitude of the latent
burden in children was appreciated at the same time that
new diagnostic tests revealed that children acquire infec-
tion at an early age [12] (One study from Haiti found that
by the age four more than 25% of children were already
infected [13]). These findings were recognised by many
endemic countries who considered that LF was a priority
as a disease that could be eliminated as public health
problem, thus improving productivity and well-being of
affected communities through reducing costs to individu-
als, communities and under-resourced health systems and
enhancing earning capacity through increased productiv-
ity in various sectors.
It has also become increasingly apparent that the two-
drug intervention provides substantial collateral health
benefits to afflicted communities and provides additional
intervention platforms for health systems. The multiplici-
ties of health benefits that derive from annual treatment
are depicted in Table 3, whilst the opportunity for integra-
tion and synergy with other health programmes are
shown in Table 4.
Table 1: Lymphatic Filariasis
• Caused by thread-like parasitic worms (Wuchereria bancrofti, Brugia malayi  and Brugia timori) that damage the human lymphatic system – 
transmitted by mosquitoes (see additional file 1)
• One of the most disabling and disfiguring of diseases
• 80+ endemic countries (Figure 1)
• 1+ billion people are at risk of infection
• 120 million people are infected. Of these...
• 43 million people have swelling of the limbs and breasts (known as lymphoedema) and genitals (known as hydrocoele), and their more 
chronic state – known as elephantiasis – in which the skin becomes enormously thickened, and is rough, hard, and fissured
• It is a disease of poverty – affecting the "poorest of the poor" – preventing those afflicted from living a normal working and social life (See 
additional file 2)
• Children acquire the disease early and are blighted for life
Table 2: Lymphatic Filariasis as a unique and successful programme
• Two drugs (largely donated or inexpensive) once per year for time limited duration
• DEC + albendazole in areas where onchocerciasis is not endemic
• Albendazole + Mectizan® where onchocerciasis is co-endemic with lymphatic filariasis
• Two major pharmaceutical companies involved
• A global disease (80 endemic countries; 1+ billion at risk) but regionalised programmatically
• Many synergistic/integration opportunities in the programme (See Table 4)
• Major successes already demonstrated
• Disability alleviation and prevention component to increase coverage and compliance via household and community self help
• Mass drug distribution – an overtly pro-poor intervention
• Intervention provides entry point to both rural and urban health settings
• Different drug distribution systems dependent on country decisions
• Separation of programmatic and GAELF responsibilities
• A free non-restrictive alliance with diverse partners
• Strong involvement of academic institutions and research funders
• Wide use of IT for dissemination and communicationFilaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/13
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Lymphatic filariasis is one of the "neglected diseases";
however its elimination appears not only feasible if
programmes are sustained over a 5-year time scale but the
programme has unique characteristics which enable it to
appeal to a wide constituency of donors (Tables 2 and 5).
Lymphatic filariasis elimination can viably contribute to
the achievement of the Millennium Development Goals
(Table 5) and represents an, as yet, unheralded global
health success story; early targets for expansion of the
programme's treatment numbers have been achieved.
Countries have become convinced of the benefits of the
programme, an active non-restrictive alliance of
committed partners has been created, and real progress in
arresting transmission has been reported from countries
which commenced treatment in 2000 and which have
completed three or four rounds of mass drug administra-
tion (MDA) – Egypt, Samoa, Vanuatu, Tanzania and Zan-
zibar. All are recording significant declines in prevalence
and intensity of microfilariaemia. Furthermore, those suf-
fering from the disease also appear to benefit from the
treatment itself – an unpredicted outcome – as the
frequency of filarial fevers are markedly reduced, and
more recently a study from Papua New Guinea has shown
a decrease in the incidence of hydrocoele (swelling of the
scrotal sac) following annual mass treatment over 4 years
[14] (although the effects on leg lymphoedema are equiv-
ocal [15]). The momentum of this success must be sus-
tained to bring hope to the 1+ billion people at risk and
remove LF as an impediment to the productivity and well-
being of poor people and free future generations from
exclusion, stigma, dependency and pain [16].
Summary
Lymphatic filariasis elimination is an "easy-to-do" inex-
pensive health intervention that provides considerable
"beyond filariasis" benefits (Tables 4 and 5), exemplifies
partnership and is easily evaluated. The success in global
health action documented here requires and deserves fur-
ther support to bring to fruition elimination of lymphatic
filariasis as a public health problem and health benefits to
poor people. A future free of lymphatic filariasis will
reduce poverty and bring better health to poor people,
prevent disability, strengthen health systems and build
partnerships.
Table 3: The benefits of Lymphatic Filariasis elimination
• Lymphatic Filariasis transmission stopped
• Intestinal helminth burden reduced
• Anaemia caused by hookworm alleviated
• Disability alleviated and skin diseases controlled
• Nutritional status improved
• Health systems strengthened
• Improved surveillance, monitoring and evaluation
• Enhanced drug distribution system
• Social mobilisation approaches improved
• Linkage of LF to other disease interventions
• Increased human resource capacity in health
• Strengthened knowledge of disease distribution
• Reduced costs to poor families who seek inappropriate treatment
• Reduced costs of surgery at district level
• Increased school attendance
• A bridge to other public-private partnerships
Table 4: Opportunities for integration and synergy with other programmes
• Vector control via bednets with malaria control
• Vector control of dengue vectors
• Intestinal helminths/Schistosomiasis programmes via schools
• Addition of DEC to iodinated/fluoridated salt (with the possibility of fortification with other micronutrients)
• Onchocerciasis control linkage in Africa where onchocerciasis/LF are co-endemic
• Linkage to guinea-worm programme for surveillance and drug distribution
• Use of National Immunisation Days for annual treatment
• Evaluation and rapid appraisal systems can link to other diseases e.g. anaemia and malaria, vector status, Loa loa, schistosomiasis, onchocerciasis
• Linkages to Vitamin A and Zithromax (Trachoma) distribution programmesFilaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/13
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If the international health community cannot deliver two
safe efficacious drugs annually – which are largely free –
which in addition to stopping transmission of lymphatic
filariasis also bring profound additional health benefits, it
is difficult to expect more complex interventions to suc-
ceed in controlling other infectious diseases.
The Global Alliance for the Elimination of Lymphatic
Filariasis has the skills, commitment and partnerships to
succeed, thereby preventing the next generation of chil-
dren being infected and subsequently afflicted by this
most stigmatising of diseases. There is, however, a need
for significant new resources to be committed to achieve
this goal.
Related websites
Global Alliance for the Elimination of Lymphatic
Filariasis
http://www.filariasis.org/
GlaxoSmithKline: Lymphatic Filariasis Programme
http://www.gsk.com/filariasis/
Mectizan® Donation Program
http://mectizan.org/lymphatic_filariasis.asp
filariasis.net
http://www.filariasis.net/
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Additional material
Table 5: Lymphatic Filariasis elimination and the Millennium Development Goals
Goal 1
• Eliminate extreme poverty and hunger
• LF is a disease of poor people in poor countries, particularly in individuals earning below $1/day. LF elimination reduces health care costs 
and increases productivity
• Reduces prevalence of underweight children by improving nutritional status, micronutrient uptake enhanced through albendazole and by 
improvement of agricultural productivity and improving household/community food security
Goal 2
• Achieve universal primary education
• LF elimination will increase capacity of poor families to access education through increased income, reduced caring for afflicted parents, 
increased school attendance and performance via drug treatment impact on intestinal helminths
• Schools can act as an entry point for drug distribution, increasing both coverage and parental awareness of the benefits
Goal 3
• Promote gender equity and empowerment
• Women play a role as drug distributors enhancing respect and empowerment
• Women's marital prospects enhanced as LF control reduces stigma of disease
Goal 4 and Goal 5
• Reduce child mortality and reduce maternal mortality
• Women's health status improves as albendazole alleviates hookworm anaemia
• Anaemia → better birth outcomes → reduced prevalence of low birth weight babies hence reduced maternal and infant mortality
Goal 6
• Combat HIV/AIDS/malaria and other diseases
• LF and malaria control interlinked by bednets, alleviation of anaemia by albendazole; drug distribution can enhance bednet coverage and re-
impregnation rates
• Albendazole impacts on child and maternal mortality via alleviation of anaemia burden
Goal 7 and Goal 8
• Ensure environmental sustainability
• Develop a Global partnership for Development
• GAELF and GPELF are an effective diverse global partnership committed to elimination of a disease of poverty by 2020.
• Elimination has been achieved in several countries bringing development benefits to poor communities
Additional File 1
Wuchereria bancrofti is the causative parasite responsible for approxi-
mately 90% of all cases of lymphatic filariasis. This animation illustrates 
the parasite's life cycle. Copyright © filariasis.net
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
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Additional File 2
"The Patient's Perspective" This video – filmed in Brazil, Haiti, India, 
Samoa and Tanzania – gives a unique insight into how lymphatic filaria-
sis affects individuals and prevents them from leading a normal life. • T1 
connection rtsp://gskdotcomrm.fplive.net/gskdotcom/lf_t1.rm (7.3 MB);• 
ISDN connection rtsp://gskdotcomrm.fplive.net/gskdotcom/lf_isdn.rm 
(1.6 MB);• Modem connection rtsp://gskdotcomrm.fplive.net/gskdotcom/
lf_modem.rm (1.2 MB). We would like to thank GlaxoSmithKline, the 
World Health Organization, the Centers for Disease Control and Preven-
tion, NEPAF, NGO Amaury Coutinho (Recife, Brazil) and all the people 
who took part in this video. This video was produced by Lipfriend Rodd 
International and supported by an education grant from 
GlaxoSmithKline.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2883-2-13-S2.txt]
Additional File 3
The ICT (Immunochromatographic Card Test) procedure for lymphatic 
filariasis is a simple, rapid test for detecting adult worm antigen in human 
blood and permits the rapid assessment of prevalence, facilitates mapping 
of disease distribution and evaluation of levels of transmission in popula-
tions under mass drug administration. This animation illustrates the ICT 
procedure. We would like to thank The Wellcome Trust for making this 
animation available to us. Copyright © The Wellcome Trust
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2883-2-13-S3.swf]
Additional File 4
Our understanding of the pathophysiology and pathogenesis of hydrocoele 
(one of the sequelae of lymphatic filariasis where fluid collects in the scro-
tal sac causing it to swell) has been greatly increased by ultrasonography 
which is able to detect adult Wuchereria bancrofti worms in scrotal lym-
phatic vessels on account of the characteristic pattern of adult worm move-
ments, known as the filarial dance sign. Examination by ultrasound is a 
non-invasive tool that has become important in clinical studies of lym-
phatic filariasis. In this digital video sequence (a transverse ultrasound 
scan of the left testis) an enlarged lymphatic vessel can be seen (arrow), 
along with one or more adult worms – detectable by their typical move-
ments – the filarial dance sign. We would like to thank Sabine Mand and 
Achim Hoerauf for making this video available to us. Reproduced with 
permission from Filaria Journal 2003, 2:3 (27 February 2003) Copyright 
© Sabine Mand and Achim Hoerauf, Bernhard Nocht Institute, Hamburg, 
Germany.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2883-2-13-S4.mpg]